Fotemustine and recurrent glioblastoma: possible new opportunities for an old drug Raffaele AddeoM. Serena De SantiMichele Caraglia Editorial 29 July 2009 Pages: 863 - 866
Inhibition of drug metabolizing cytochrome P450s by the aromatase inhibitor drug letrozole and its major oxidative metabolite 4,4′-methanol-bisbenzonitrile in vitro Seongwook JeongMargaret M. WooZeruesenay Desta Original Article 07 February 2009 Pages: 867 - 875
Dose-finding study of docetaxel, oxaliplatin, and S-1 for patients with advanced gastric cancer Dae Young ZangDae Hyun YangJung Han Kim Original Article 04 February 2009 Pages: 877 - 883
Downregulation of matrix metalloprotease-9 and urokinase plasminogen activator by TX-1877 results in decreased tumor growth and metastasis on xenograft model of rectal cancer Kotaro MiyakeMitsuo ShimadaHitoshi Hori Original Article 12 February 2009 Pages: 885 - 892
Oxaliplatin, irinotecan, and fluorouracil/folinic acid in advanced gastric cancer: a multicenter phase II trial of the Southern Italy Cooperative Oncology Group Pasquale ComellaVito LorussoLuca Franco Original Article 03 February 2009 Pages: 893 - 899
Bleomycin, vinorelbine and trofosfamide in relapsed stage IV cutaneous malignant melanoma patients Jens AtzpodienLars MorawekMartina Reitz Original Article 20 February 2009 Pages: 901 - 905
Long-term results of gemcitabine plus oxaliplatin with and without rituximab as salvage treatment for transplant-ineligible patients with refractory/relapsing B-cell lymphoma Gaetano CorazzelliGaetana CapobiancoAntonio Pinto Original Article 15 February 2009 Pages: 907 - 916
Irinotecan and oxaliplatin combination as the first-line treatment for patients with advanced non-small cell lung cancer Myung Hee ChangKyoung Ha KimKeunchil Park Original Article 17 February 2009 Pages: 917 - 924
The relative activity of cisplatin, oxaliplatin and satraplatin in testicular germ cell tumour sensitive and resistant cell lines Jackie PerryThomas PowlesSimon Joel Original Article 05 March 2009 Pages: 925 - 933
A phase I study of gemcitabine given via intrahepatic pump for primary or metastatic hepatic malignancies Archie N. TseNian WuNancy Kemeny Original Article 17 February 2009 Pages: 935 - 944
Analysis of feasibility and toxicity of concurrent chemoradiotherapy with S-1 for locally advanced squamous cell carcinoma of the head and neck in elderly cases and/or cases with comorbidity Mamoru TsukudaJunichi IshitoyaYukiko Yamashita Original Article Open access 15 February 2009 Pages: 945 - 952
Prostaglandin synthase 2/cyclooxygenase 2 (PTGS2/COX2) 8473T>C polymorphism associated with prognosis for patients with colorectal cancer treated with capecitabine and oxaliplatin Jong Gwang KimYee Soo ChaeSoo-Han Jun Original Article 15 February 2009 Pages: 953 - 960
Cediranib (recentin, AZD2171) reverses ABCB1- and ABCC1-mediated multidrug resistance by inhibition of their transport function Li-yang TaoYong-ju LiangLi-wu Fu Original Article 03 March 2009 Pages: 961 - 969
Chemoprotection and enhancement of cancer chemotherapeutic efficacy of cyclophosphamide in mice bearing Ehrlich ascites carcinoma by diphenylmethyl selenocyanate Pramita ChakrabortyUgir Hossain SkSudin Bhattacharya Original Article 17 February 2009 Pages: 971 - 980
Delivery of high levels of anti-proliferative nucleoside triphosphates to CYP3A-expressing cells as a potential treatment for hepatocellular carcinoma Deidre A. MacKennaAnnika MontagMark D. Erion Original Article 13 March 2009 Pages: 981 - 991
Distinct mechanistic activity profile of pralatrexate in comparison to other antifolates in in vitro and in vivo models of human cancers E. IzbickaA. DiazM. Saunders Original Article Open access 17 February 2009 Pages: 993 - 999
Polymorphisms in p53, GSTP1 and XRCC1 predict relapse and survival of gastric cancer patients treated with oxaliplatin-based adjuvant chemotherapy Zhao-Hui HuangDong HuaXiang Du Original Article 27 February 2009 Pages: 1001 - 1007
In vivo activity of gemcitabine-loaded PEGylated small unilamellar liposomes against pancreatic cancer Donato CoscoAlessandra BulottaMassimo Fresta Original Article 05 March 2009 Pages: 1009 - 1020
A phase II study of capecitabine in the treatment of ovarian cancer resistant or refractory to platinum therapy: a multicentre Italian trial in ovarian cancer (MITO-6) trial Carmela PisanoAlessandro MorabitoSandro Pignata Original Article 06 March 2009 Pages: 1021 - 1027
Bone marrow CFU-GM and human tumor xenograft efficacy of three tubulin binding agents Leslie S. KurtzbergStephanie D. RothBeverly A. Teicher Original Article 10 March 2009 Pages: 1029 - 1038
Perturbation of DNA repair pathways by proteasome inhibitors corresponds to enhanced chemosensitivity of cells to DNA damage-inducing agents Takashi TakeshitaWenwen WuTomohiko Ohta Original Article Open access 10 March 2009 Pages: 1039 - 1046
The acute effects of CMF-based chemotherapy on maxillary periodontal microcirculation Dan M. J. MilsteinRick BezemerCan Ince Original Article 25 July 2009 Pages: 1047 - 1052
A sphingosine kinase inhibitor induces cell death in temozolomide resistant glioblastoma cells Meryem BektasStewart P. JohnsonHenry S. Friedman Short Communication 12 July 2009 Pages: 1053 - 1058
